Humanigen, Inc. (HGEN) Income Statement Analysis

See more : Madrigal Pharmaceuticals, Inc. (MDGL) Income Statement Analysis – Financial Results

Complete financial analysis of Humanigen, Inc. (HGEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Humanigen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

América Móvil, S.A.B. de C.V. (AMXB.MX) Income Statement Analysis – Financial Results
SThree plc (STEM.L) Income Statement Analysis – Financial Results
Bauhaus International (Holdings) Limited (0483.HK) Income Statement Analysis – Financial Results
HITECHPROS Société anonyme (ALHIT.PA) Income Statement Analysis – Financial Results
Hi-Level Technology Holdings Limited (8113.HK) Income Statement Analysis – Financial Results

Humanigen, Inc. (HGEN)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.humanigen.com

About Humanigen, Inc.

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called 'cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.

Metric	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Revenue	2.51M	3.60M	312.00K	0.00	0.00	0.00	0.00	0.00	0.00	44.00K	6.10M	20.26M	17.71M	589.00K
Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	2.51M	3.60M	312.00K	0.00	0.00	0.00	0.00	0.00	0.00	44.00K	6.10M	20.26M	17.71M	589.00K
Gross Profit Ratio	100.00%	100.00%	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Research & Development	55.21M	213.12M	72.71M	2.62M	2.22M	11.17M	10.45M	16.72M	26.57M	32.64M	24.52M	18.51M	18.89M	22.86M
General & Administrative	15.61M	23.25M	15.80M	6.33M	9.11M	7.87M	8.38M	14.30M	10.15M	8.31M	5.06M	4.01M	4.94M	5.19M
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	15.61M	23.25M	15.80M	6.33M	9.11M	7.87M	8.38M	14.30M	10.15M	8.31M	5.06M	4.01M	4.94M	5.19M
Other Expenses	0.00	-1.61M	-1.00K	-1.00K	324.00K	431.00K	125.00K	-213.00K	-154.00K	-39.00K	113.00K	-8.00K	915.00K	348.00K
Operating Expenses	70.82M	236.37M	88.51M	8.94M	11.33M	19.03M	18.83M	31.02M	36.72M	40.95M	29.58M	22.52M	23.84M	28.05M
Cost & Expenses	70.82M	236.37M	88.51M	8.94M	11.33M	19.03M	18.83M	31.02M	36.72M	40.95M	29.58M	22.52M	23.84M	28.05M
Interest Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	29.00K	88.00K	86.00K	0.00	0.00	0.00	0.00
Interest Expense	2.92M	2.26M	1.34M	1.35M	852.00K	3.06M	131.00K	842.00K	1.21M	1.09M	0.00	0.00	0.00	0.00
Depreciation & Amortization	492.00K	-1.61M	-1.00K	-1.00K	19.00K	48.00K	102.00K	197.00K	310.00K	298.00K	304.00K	595.00K	843.00K	844.00K
EBITDA	-67.81M	-234.39M	-88.20M	-8.95M	-10.99M	-18.55M	-18.60M	-31.00M	-36.47M	-40.56M	-23.18M	-1.67M	-5.28M	-26.62M
EBITDA Ratio	-2,697.37%	-6,519.75%	-28,268.91%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-92,190.91%	-380.09%	-8.25%	-29.81%	-4,519.35%
Operating Income	-68.30M	-232.77M	-88.20M	-8.94M	-11.33M	-19.03M	-18.83M	-34.35M	-36.72M	-40.91M	-23.48M	-2.27M	-6.12M	-27.46M
Operating Income Ratio	-2,716.95%	-6,474.88%	-28,268.59%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-92,975.00%	-385.08%	-11.19%	-34.57%	-4,662.65%
Total Other Income/Expenses	-2.43M	-3.88M	-1.34M	-1.35M	-673.00K	-2.96M	-8.19M	-1.03M	-1.28M	-1.04M	-27.00K	35.00K	1.02M	639.00K
Income Before Tax	-70.73M	-236.65M	-89.54M	-10.29M	-12.00M	-21.99M	-27.02M	-35.38M	-38.00M	-41.95M	-23.51M	-2.23M	-5.10M	-26.82M
Income Before Tax Ratio	-2,813.44%	-6,582.73%	-28,697.12%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-95,336.36%	-385.52%	-11.02%	-28.79%	-4,554.16%
Income Tax Expense	-492.00K	2.26M	1.34M	1.35M	179.00K	3.49M	256.00K	629.00K	1.06M	1.05M	140.00K	-43.00K	-108.00K	-19.00K
Net Income	-70.24M	-238.91M	-90.87M	-11.64M	-12.00M	-21.99M	-27.02M	-35.38M	-38.00M	-41.95M	-23.51M	-2.23M	-5.10M	-26.81M
Net Income Ratio	-2,793.87%	-6,645.70%	-29,125.32%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-95,336.36%	-385.52%	-11.02%	-28.79%	-4,550.93%
EPS	-1.18	-4.08	-2.46	-0.52	-0.63	-7.34	-13.92	-42.88	-46.09	-69.13	-448.66	-46.17	-97.33	-85.16
EPS Diluted	-1.18	-4.08	-2.46	-0.52	-0.63	-7.34	-13.92	-42.88	-46.09	-69.13	-448.66	-46.17	-97.33	-85.16
Weighted Avg Shares Out	59.49M	58.53M	36.96M	22.36M	18.95M	3.00M	1.94M	825.00K	824.48K	606.76K	52.40K	48.34K	52.40K	314.77K
Weighted Avg Shares Out (Dil)	59.49M	58.53M	36.96M	22.36M	18.95M	3.00M	1.94M	825.00K	824.48K	606.76K	52.40K	48.34K	52.40K	314.77K

Levi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action Settlement

March 5, 2024accesswire.com

NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Humanigen, Inc. (NASDAQ:HGEN). The settlement provides for a fund of $3,000,000 to...

Levi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action Settlement

February 29, 2024accesswire.com

NEW YORK, NY / ACCESSWIRE / February 29, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Humanigen, Inc. (NASDAQ:HGEN). The settlement provides for a fund of $3,000,000 to...

HGEN Stock Alert: Why Humanigen Just Filed for Ch. 11 Bankruptcy

January 5, 2024investorplace.com

Humanigen (OTCMKTS: HGEN ) stock is falling hard on Friday after the company filed for Chapter 11 bankruptcy protection. This bankruptcy filing comes after Humanigen failed to secure regulatory approval for its Covid-19 treatment lenzilumab.

COVID-19 treatment developer Humanigen files for Chapter 11 bankruptcy

January 4, 2024reuters.com

Drug developer Humanigen HGEN.PK has filed for voluntary Chapter 11 bankruptcy, according to a court filing, after struggling to get regulatory approval for its COVID-19 treatment.

Humanigen Announces First Participant Dosed in RATinG Trial of Lenzilumab for Early Treatment of Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation

August 7, 2023newsfilecorp.com

The RATinG (Risk Adapted Therapy in Acute GvHD) is the first trial to explore granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralization for the early treatment of participants with high-risk acute Graft versus Host Disease Planned interim assessment expected in 2024 following treatment...

Humanigen stock removed from S&P Total Market Index as firm faces bankruptcy

July 28, 2023proactiveinvestors.com

Humanigen Inc shares have plummeted more than 90% over the past month, and now trades at a little over a penny per share, after the clinical-stage biopharmaceutical company said it is facing bankruptcy after negotiations for a reverse merger with...

Why Is Humanigen (HGEN) Stock Down 72% Today?

July 25, 2023investorplace.com

Humanigen (NASDAQ: HGEN ) stock is falling hard on Tuesday after the company warned investors it can't keep listing requirements. According to a filing from the company, it is no longer compliant with Nasdaq listing standards.

Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress

June 9, 2023newsfilecorp.com

Of the 14 participants enrolled and treated with lenzilumab plus azacitidine, ten are evaluable with three to eighteen months of follow-up and all ten have had a rapid clinical response Building upon previously reported positive clinical responses, these additional data...

Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia

April 17, 2023zacks.com

Humanigen's (HGEN) shares surge after presenting promising early results of its Precision Approach to Chronic Myelomonocytic Leukemia study of lenzilumab in chronic myelomonocytic leukemia.